Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation

Author： Szmania S Yi Q Cottler-Fox M Rosen NA Freeman J Kordsmeier BJ Moreno A Shi J Barlogie B Tricot G van Rhee F

ISSN： 1465-3249

Source： Cytotherapy, Vol.7, Iss.4, 2005-09, pp. : 374-384

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of a surrogate angiogenic potency assay for clinical-grade stem cell production

By Lehman Nicholas Cutrone Rochelle Raber Amy Perry Robert van't Hof Wouter Deans Robert Ting Anthony E. Woda Juliana

Cytotherapy, Vol. 14, Iss. 8, 2012-09 ,pp. : 994-1004

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML

By Litzow Mr Dietz Ab Bulur Pa Butler Gw Gastineau Da Hoering A Fink Sr Letendre L Padley Dj Paternoster Sf Tefferi A Vuk-Pavlović S

Cytotherapy, Vol. 8, Iss. 3, 2006-05 ,pp. : 290-298

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Clinical-grade manufacturing of DC from CD14 + precursors: experience from phase I clinical trials in CML and malignant melanoma

By Dietz AB Padley DJ Butler GW Maas ML Greiner CW Gastineau DA Vuk-pavlović S

Cytotherapy, Vol. 6, Iss. 6, 2004-12 ,pp. : 563-570

Ashgate Publishing Ltd

Access to resources Recommend Favorite

DC-based cancer vaccines: lessons from clinical trials

By Brody JD Engleman EG

Cytotherapy, Vol. 6, Iss. 2, 2004-04 ,pp. : 122-127

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Development of a technology platform for large-scale clinical grade production of DC

By Adamson L Palmborg A Svensson A Lundqvist A Hansson M Kiessling R Masucci G Mellstedt H Pisa P

Cytotherapy, Vol. 6, Iss. 4, 2004-08 ,pp. : 363-371

Ashgate Publishing Ltd

Access to resources Recommend Favorite